Orthonotes
Orthonotes
by the.bonestories
v3.0 Fusion
v3.0 Fusion
PubMed Original Article Evidence Unclassified

Solitary plasmacytoma.

Journal of surgical oncology | 1983 | Kayrouz T, Jose B, Chu AM, Scott RM

In-App Reader

Open Source

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Source
PubMed
Type
Original Article
Evidence
Unclassified

Abstract

[Indexed for MEDLINE] 6. Curr Hematol Malig Rep. 2018 Jun;13(3):227-235. doi: 10.1007/s11899-018-0452-z. How We Manage Patients with Plasmacytomas. Fotiou D(1), Dimopoulos MA(1), Kastritis E(2). Author information: (1)Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. (2)Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. ekastritis@gmail.com. PURPOSE OF REVIEW: To discuss the diagnostic approach, treatment options, and future considerations in the management of plasmacytomas, either solitary or in the context of overt multiple myeloma (MM). RECENT FINDINGS: Advanced imaging techniques such as whole-body magnetic resonance imaging and positron emission tomography/computerized tomography are essential for the diagnostic workup of solitary plasmacytomas (SP) to rule out the presence of other disease foci. The role of flow cytometry and clonal plasma cell detection is currently under study together with other prognostic factors for the identification of patients with SP at high risk of progression to overt MM. Solitary plasmacytomas are treated effectively with local radiotherapy whereas systemic therapy is required at relapse. Clonal plasma cells that accumulate at extramedullary sites have distinct biological characteristics. Patients with MM and soft tissue involvement have poor outcomes and should be treated as ultra-high risk. A revised definition of SP that distinguishes between true solitary clonal PC accumulations and SP with minimal bone marrow involvement should be considered to guide an appropriate therapeutic and follow-up approach. Future studies should be conducted to determine optimum treatment approaches for patients with MM and paraskeletal or extramedullary disease. DOI: 10.1007/s11899-018-0452-z

Linked Wiki Topics

This article has not been linked to a wiki topic yet.

Linked Cases

This article has not been linked to a case yet.

Linked Atlases

This article has not been linked to an atlas yet.